Revolutionizing Atopic Dermatitis

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Learn more about the latest research in atopic dermatitis from Raj Chovatiya, MD, PhD, MSCI; Robert Sidbury, MD; David Rosmarin, MD; Amy Paller, MD; Melinda Gooderham, MD, MSc, FRCPC; and Jonathan Silverberg, MD, PhD, MPH.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Catch up on all clinical pearls from the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

The inaugural RAVE conference begins today in Chicago, Illinois.

Three distinct congresses known as RAVE (Revolutionizing Atopic Dermatitis, Alopecia Areata, and Vitiligo) will be held June 8-10, in Chicago, Illinois.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.

The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.